Adam Smith Conferences

Adam Smith Conferences Adam Smith Conferences is the market leader for conferences and exhibitions.

Since 1992, Adam Smith Conferences has organized and continues to successfully organize a number of business forums that attract thousands of government and business executives every year. Many of these events are now established annual gatherings, which offer unrivalled insights into market trends and developments, investment opportunities, and commercial strategies for success. Conferences of ou

r company have provided platforms for debate across many industry sectors including: energy, transport, banking & financial services, consumer goods, real estate, investments, pharmaceuticals, mining & metals, pulp & paper, automotive, agribusiness and IT. Our events have been focusing on the markets of Western, Central and South-Eastern Europe and Asia. The consistent high quality of our events has earned a high reputation among economic and industrial leaders, who participate in our conferences, provide delegates with access to the most up-to-date and proven information about the market, and stimulate business communication.

Last week was packed with important events, including the Eurasian Pharmaceutical Forum. But beyond that, there were man...
11/03/2025

Last week was packed with important events, including the Eurasian Pharmaceutical Forum. But beyond that, there were many other significant developments in healthcare policy and regulation across the region.

Together with Outpost Eurasia, we present the latest weekly Healthcare Policy & Regulatory Digest for Eastern Europe, South Caucasus, and Central Asia (EECA), covering the period March 3–9, 2025.

📩 Read the Digest here: https://t.me/eurasianpharma/97

The session on "Effective Data Management in Clinical Trials: Risks, Strategies, and Regulatory Decisions" at the Eurasi...
05/03/2025

The session on "Effective Data Management in Clinical Trials: Risks, Strategies, and Regulatory Decisions" at the Eurasian Pharmaceutical Forum 2025 delved into the complexities of clinical research, focusing on data integrity, regulatory compliance, and strategic risk management.

Experts discussed best practices for handling clinical trial data, the role of digitalization in improving transparency and efficiency, and how regulatory frameworks impact research processes.

Closing the discussion, speakers expressed their optimism about the future of clinical research in the region.

A big thank you to all speakers and participants for an insightful session! The development of clinical research is a key driver for pharmaceutical innovation, and we look forward to seeing continued progress in this area.

The session on "Collaboration between Local and International Players: Strategic Partnerships to Expand Distribution and...
05/03/2025

The session on "Collaboration between Local and International Players: Strategic Partnerships to Expand Distribution and Adapt Products to Regional Markets" at the Eurasian Pharmaceutical Forum 2025 focused on the practical aspects of international cooperation in the pharmaceutical industry.

Under the moderation of Zafar Vakhidov, Counsel of APRFD KAZ & AIPM UZB, Partner of Vakhidov & Partners, experts explored how global companies can leverage partnerships with local players to accelerate product launches in EAEU countries.

A key point of debate was the legal and operational risks that may arise in international collaborations. Speakers shared insights on navigating regulatory frameworks, ensuring compliance, and mitigating challenges in cross-border partnerships.

Wrapping up the session, Zafar Vakhidov highlighted his confidence in the future of the regional market:
"I believe that, overall, the pharmaceutical industry in the Central Asian region will continue to grow in a healthy and sustainable way."

A big thank you to all speakers and participants for a productive and insightful discussion!

The Analytical Session of the Eurasian Pharmaceutical Forum 2025 brought together industry experts and regulators for an...
05/03/2025

The Analytical Session of the Eurasian Pharmaceutical Forum 2025 brought together industry experts and regulators for an in-depth discussion of pharmaceutical market trends based on analytics.

As part of the Expert Analytical Session: Overview of Pharmaceutical Markets of EAEU Countries, Results of 2024 and Forecasts for 2025, moderator Alexander Ivanov, Head of Strategic Consulting at Aston Health, opened the discussion by highlighting its importance:

"I am very pleased to open what is probably the most traditional session of our conference - an analytical session. It is a key part of every event. Today we have an exciting line-up of participants: representatives from analytical agencies who will share their insights on pharmaceutical market trends, key drivers and recent changes. We also have regulators who will discuss the latest regulatory initiatives and their impact on market dynamics.

The session was filled not only with valuable data and key takeaways but also with engaging debates.

🔹 A big appreciation to all speakers and participants for the insightful analysis and lively discussion that made this session so impactful!

The second day of the Forum agenda continues with an insightful discussion on drug labelling systems.Industry experts an...
05/03/2025

The second day of the Forum agenda continues with an insightful discussion on drug labelling systems.

Industry experts and regulators explored the impact of labelling on transparency, safety and the pharmaceutical supply chain. Speakers shared insights and results from drug labelling and traceability projects implemented in different countries, highlighting best practices and future perspectives.
The session provided a valuable platform for sharing experiences and discussing the challenges and opportunities in adapting labelling regulations.

🙏 Thank you to all speakers and participants for an engaging and insightful discussion!

Eurasian Pharmaceutical Forum 2025
hashtag hashtag

The final session of the first day of the Eurasian Pharmaceutical Forum 2025 closed with an engaging discussion on digit...
04/03/2025

The final session of the first day of the Eurasian Pharmaceutical Forum 2025 closed with an engaging discussion on digitalisation in healthcare, covering key trends in AI, telemedicine and the formation of a unified digital healthcare space.

🙏 A big thank you to all Forum participants for such valuable insights and discussions! Another exciting day of the programme ahead!

The panel session "Innovation and Patent Disputes: Balancing Intellectual Property Protection and Access to Medicines" b...
04/03/2025

The panel session "Innovation and Patent Disputes: Balancing Intellectual Property Protection and Access to Medicines" brought together industry leaders, legal experts, and regulators to discuss the complexities of pharmaceutical patents, innovation incentives, and patient access to medicines.

🙏 Thank you to all the speakers for an insightful and engaging discussion! Your expertise is invaluable in shaping the future of pharmaceutical innovation and accessibility.

Eurasian Pharmaceutical Forum 2025

The panel discussion on "Pricing in the Countries of the Eurasian Region: Challenges and Solutions for 2024-2025" brough...
04/03/2025

The panel discussion on "Pricing in the Countries of the Eurasian Region: Challenges and Solutions for 2024-2025" brought together key regulators, industry experts, and pharmaceutical representatives to address pricing policies and access to medicines.

💡 The discussion focused on pricing strategies, regulatory approaches, and access to medicines across EAEU and CIS countries, with particular attention to harmonization efforts and sustainable market solutions.

A huge thank you to all the speakers for such a dynamic and insightful discussion!

Roman Dray, Director of the Research and Development Department of ГЕРОФАРМ, shared his perspective on the regulatory pr...
04/03/2025

Roman Dray, Director of the Research and Development Department of ГЕРОФАРМ, shared his perspective on the regulatory process and the challenges associated with drug approval and registration.

"The regulatory authorities are indeed making efforts to meet us halfway. However, this takes time - six months to achieve compliance and then another year for registration through the national process.
Recognition in a country is particularly difficult for a drug that is not yet on the market there and does not have a national registration certificate. As national procedures are still in place, one way we work around this is to first register the medicine in the country and then bring it into compliance. This approach works faster because we have access to the dossier and direct communication with the applicant - that is, with us - which allows us to respond more efficiently to requests".

Eurasian Pharmaceutical Forum 2025

ARDAK TULEGENOVA, Head of the Department for the Improvement of the State Pharmacopoeia of the Republic of Kazakhstan an...
04/03/2025

ARDAK TULEGENOVA, Head of the Department for the Improvement of the State Pharmacopoeia of the Republic of Kazakhstan and the EAEU, emphasized the critical role of the EAEU Pharmacopoeia in ensuring the quality of medicines entering the market.

"The EAEU Pharmacopoeia sets the quality criteria for medicines and serves as the foundation for drug registration and examination within the union. I simply cannot imagine a situation where an expert evaluation could be conducted without this fundamental document.

I hope that this year we will finalize the fourth part of the first volume, completing the general requirements of the Pharmacopoeia. After that, we face the challenging task of developing the second volume and the complex second part dedicated to private pharmacopoeial monographs."

Eurasian Pharmaceutical Forum 2025

Talgat Momyshev, Director of the Technical Regulation and Accreditation Department, EEC, at the Eurasian Pharmaceutical ...
04/03/2025

Talgat Momyshev, Director of the Technical Regulation and Accreditation Department, EEC, at the Eurasian Pharmaceutical Forum 2025.

"The Eurasian system for drug registration is now operating at full scale, and we are witnessing a sharp increase in application submissions. The total number of applications has approached 28,000, with more than 9,000 registration certificates already issued.

At the same time, I would like to remind everyone that the transition period—along with the simplified compliance procedure compared to new registration—will end in December 2025. This deadline will not be extended."

Elena Popova, Senior Director, Association of International Pharmaceutical Manufacturers in the Russian Federation, mode...
04/03/2025

Elena Popova, Senior Director, Association of International Pharmaceutical Manufacturers in the Russian Federation, moderated the session "Unified Registration of Medicines in the EAEU Countries and Uzbekistan. Cooperation without Borders!" at the Eurasian Pharmaceutical Forum 2025

"The forum has already established itself as a major regional professional platform where key issues of healthcare integration and system development within the EAEU are traditionally discussed. The regulatory session, in particular, continues to play a crucial role.

We have already heard in the first session—and this was echoed in almost every presentation—that market access for medicines consists of several key components. The first and foremost is, of course, market entry, ensuring drug availability through its regulatory approval."

MARIA SHIPULEVA, General Manager, AstraZeneca Kazakhstan, highlighted the role of innovative pharmaceutical companies in...
04/03/2025

MARIA SHIPULEVA, General Manager, AstraZeneca Kazakhstan, highlighted the role of innovative pharmaceutical companies in Kazakhstan.

"Challenges exist, but they are mostly tactical. What is truly encouraging is that we, as innovative companies, are being heard.

Our primary focus is not on localizing production—our focus is on conducting research, educating healthcare professionals, and driving diagnostic projects.

I am confident that those involved in diagnostics in Kazakhstan could achieve even more if the opportunities were expanded. And the more possibilities we see, the more we will invest."

Eurasian Pharmaceutical Forum 2025

Dr. Toylan Şenel, Head of F.Hoffmann-La Roche, Central Asia (Kazakhstan, Uzbekistan, Kyrgyzstan, Tajikistan, Mongolia) s...
04/03/2025

Dr. Toylan Şenel, Head of F.Hoffmann-La Roche, Central Asia (Kazakhstan, Uzbekistan, Kyrgyzstan, Tajikistan, Mongolia) shared insights on the increasing healthcare expenditures and the challenges of funding pharmaceutical access in a rapidly changing environment.

"From this perspective, what was very interesting to observe at the beginning was the growth in pharmaceutical spending. And this increase cannot be attributed solely to the introduction of compulsory health insurance and expanded coverage.

We must acknowledge that our society is aging, our population is growing, and, as a result, healthcare expenditures are rising as well. Even with the best system we could envision - whether it is the Norwegian model or another approach we might adopt - we will never have absolutely sufficient funds to cover all the medical needs that exist."

Eurasian Pharmaceutical Forum 2025

DMITRY KOZENKOV, Head of Pfizer Representative Office in Kazakhstan highlighted an important perspective on pharmaceutic...
04/03/2025

DMITRY KOZENKOV, Head of Pfizer Representative Office in Kazakhstan highlighted an important perspective on pharmaceutical investments.

"It is worth noting that OECD countries, which Kazakhstan aims to join, view spending on innovative medicines more as an investment rather than a budgetary expense.

I hope that with the reforms currently being implemented by the Ministry of Health and the Center for Health Development, we will move in the same direction. This shift will ultimately benefit the people of Kazakhstan and the populations of the countries represented here today."

Eurasian Pharmaceutical Forum 2025

Adilet Nazarbayev, General Director of Johnson & Johnson Kazakhstan, addressed a critical aspect of medicine accessibili...
04/03/2025

Adilet Nazarbayev, General Director of Johnson & Johnson Kazakhstan, addressed a critical aspect of medicine accessibility, emphasizing that challenges go beyond regulatory approvals.

"When we talk about medicine accessibility, we usually focus on registration timelines and the inclusion of drugs in regulatory lists. However, there are still significant challenges in the physical availability of medicines.

Even after a drug has passed all regulatory approvals, there are unfortunate cases where patients still cannot physically access the treatment they need.

Today, with representatives from regulatory bodies and businesses in attendance, I would like to highlight these issues and discuss possible solutions."

This discussion underscores the importance of a comprehensive approach to ensuring real access to medicines for patients.

Larisa Matveeva, Executive Director, Association of International Pharmaceutical Manufacturers in the Russian Federation...
04/03/2025

Larisa Matveeva, Executive Director, Association of International Pharmaceutical Manufacturers in the Russian Federation, shared key insights at the Eurasian Pharmaceutical Forum 2025.

"Looking at the experience of the past 3-4 years and the internal surveys conducted within our association, more than 70% of our members plan to continue launching new medicines in 2025-2026. This is an encouraging figure.

Over the past year alone, more than 120 original drugs have been registered, along with approximately 250 generic medicines."

These numbers highlight the ongoing commitment of pharmaceutical companies to innovation and expanded patient access to essential treatments.

GULNARA KULKAYEVA, Chairman of the Board of the National Scientific Center for Health Development named after Salidat Ka...
04/03/2025

GULNARA KULKAYEVA, Chairman of the Board of the National Scientific Center for Health Development named after Salidat Kairbekova, spoke at the plenary session of the Eurasian Pharmaceutical Forum 2025

Gulnara Kulkayeva delivered a key presentation during the plenary session, highlighting an important initiative currently being developed by the Ministry of Health under the mandate of the Head of State.

She emphasized:

"Many of you are aware that, following the directive of the Head of State, the Ministry is currently working on the development of a unified package of basic state medical care, designed to align with budgetary capabilities.

As part of this initiative, a single comprehensive medical care package is being formed, ensuring that nearly all conditions requiring dynamic monitoring are included."

Address

Republic Of Kazakhstan, Street Zharokova, D. 257, Of. 201
Moscow
050012

Telephone

+74957852208

Website

Alerts

Be the first to know and let us send you an email when Adam Smith Conferences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Adam Smith Conferences:

Shortcuts

Share

Our Story

Since 1992 Adam Smith Conferences have been developing a range of high-calibre industry forums, which attract thousands of key decision makers from governments and industry each year. Many of these events are now the established annual gatherings for industry players, which offer unrivalled insights into market trends and developments, investment opportunities, and commercial strategies for success. Adam Smith Conferences have provided platforms for debate across many industry sectors including: energy, transport, banking & financial services, retail and FMCG, real estate, investments, pharmaceuticals, mining & metals, pulp & paper, automotive, agribusiness, and IT. Our experience and extensive contacts, developed over the last twenty years, have enabled us to create a highly specialised niche and we are proud that today we are the market leader for conferences in Russia and the CIS! The consistent high quality of our events has given rise to a reputation for excellence, ensuring that Adam Smith Conferences provide the most fertile ground for participants to gain up-to-the-minute market intelligence and invaluable opportunities to network and generate new business.